Biogen (BIIB) PT Raised to $275 at Oppenheimer

April 1, 2026 8:07 AM

Oppenheimer analyst Jay Olson raised the price target on Biogen (NASDAQ: BIIB) to $275.00 (from $250.00) while maintaining a Outperform rating.

No results found